Research Progress of Biomarkers in Early Diagnosis and Monitoring in Newborn with Brain Injury
10.13241/j.cnki.pmb.2017.27.045
- VernacularTitle:生物标记物对脑损伤患儿早期诊断及监测价值的研究进展
- Author:
Huiyan MAI
;
Bin WANG
;
Yanchen CHEN
;
Yan CHENG
;
Jun CHEN
- Keywords:
Neonatal brain injury;
Biomarker;
Research progress
- From:
Progress in Modern Biomedicine
2017;17(27):5376-5379
- CountryChina
- Language:Chinese
-
Abstract:
Brain injury is one of the most serious diseases in neonatal period,which can cause cerebral palsy,motor development delay,cognitive dysfunction and learning difficulties and other sequelae,and severely affects the health development and quality of life of the newborn.Neonatal brain injury (NBI) is a wide range of diseases caused by a variety of causes,its clinical manifestations lack specificity,clinically,it is difficult to judge the severity,duration and the time of prenatal injury,and it has been paid much attention to by scientific researchers and clinicians.At present,imaging method is a major means of NBI diagnosis,but imaging examination is usually a lag and limitations.Levels of humoral biomarkers change early after brain injury,and early brain injury can be predicted by detecting their changes.In recent years,a variety of sensitive brain damage biomarkers have been detected in various body fluids of newborns,mainly including neuron-specific enolase (NSE),ubiquitin carboxyl hydrolase L1 (UCH L1),S100B protein,tau protein,myelin basic protein (MBP),glial fibrillary acidic protein (GFAP) and activin A and so on.the application and research progress of these commonly used biomarkers in NBI are reviewed in this paper.
